TapewireFind a company

person · Reporting owner

Goldan Keith A.

Disclosed activity across 3 companies

Tapewire entity
42383
SEC CIK
0001495411

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ABEONA THERAPEUTICS INC.ABEO · Entity 5808DirectorApril 01, 2026April 07, 2026
OptiNose, Inc.OPTN · Entity 79464Chief Financial OfficerMarch 16, 2022March 17, 2022
Syndax Pharmaceuticals IncSNDX · Entity 4578Chief Financial OfficerJune 01, 2026June 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ABEONA THERAPEUTICS INC.

Report date April 01, 2026 · Filed April 07, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect32,751 Reported balance After 2026-04-01 transaction · row 1
1 source row

Row 1 · 2026-04-01 · Grant · Acquired 32,751 · Balance 32,751

F1: All of the restricted stock will vest on April 1, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: All of the restricted stock will vest on April 1, 2027.

OptiNose, Inc.

Report date March 16, 2022 · Filed March 17, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect141,726 Reported balance After 2022-03-16 transaction · row 1
1 source row

Row 1 · 2022-03-16 · Sale · Disposed 4,617 · Balance 141,726

F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Syndax Pharmaceuticals Inc

Report date June 01, 2026 · Filed June 02, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect139,252 Reported balance After 2026-06-01 transaction · row 1
1 source row

Row 1 · 2026-06-01 · Sale · Disposed 1,177 · Balance 139,252

F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 01, 2026 Filed Jun 2, 2026 20:30 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 SaleCommon Stock 1,177 $18.99 $22,351.23
Disclosure

SEC source: 0001193125-26-253603 · ownership.xml · nonDerivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 139,252

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.

Read SEC document
April 01, 2026 Filed Apr 7, 2026 12:47 UTC ABEONA THERAPEUTICS INC. ABEO · Entity 5808 GrantCommon Stock 32,751 $0.00 $0.00
Disclosure

SEC source: 0001493152-26-015456 · ownership.xml · nonDerivative · entry 1

Goldan Keith A. · CIK 0001495411 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,751

F1 · shares: All of the restricted stock will vest on April 1, 2027.

Read SEC document
February 09, 2026 Filed Feb 10, 2026 13:59 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 SaleCommon Stock 3,410 $21.03 $71,705.48
Disclosure

SEC source: 0001193125-26-043813 · ownership.xml · nonDerivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,429

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.

Read SEC document
February 06, 2026 Filed Feb 6, 2026 22:53 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 SaleCommon Stock 2,082 $20.62 $42,930.84
Disclosure

SEC source: 0001193125-26-041497 · ownership.xml · nonDerivative · entry 4

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 143,839

F4 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 22:53 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 GrantStock Options (Right to buy) · Derivative 118,000 $20.43 Strike: $20.43 $2,410,740.00
Disclosure

SEC source: 0001193125-26-041497 · ownership.xml · derivative · entry 5

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,000

Underlying: Common Stock · 118,000 shares

Expires 2036-02-04

F5 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 22:53 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 GrantCommon Stock 30,750 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-041497 · ownership.xml · nonDerivative · entry 3

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 145,921

F3 · shares: Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 22:53 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 GrantCommon Stock 21,500 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-041497 · ownership.xml · nonDerivative · entry 2

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,171

F2 · shares: Award of restricted stock units ("RSUs"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested.

Read SEC document
January 30, 2026 Filed Feb 6, 2026 22:53 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 OtherCommon Stock 1,219 $8.48 $10,337.12
Disclosure

SEC source: 0001193125-26-041497 · ownership.xml · nonDerivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,671

F1 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,219 shares by the Reporting Person on 1/30/2026 pursuant to the Issuer's Employee Stock Purchase Plan.

Read SEC document
December 01, 2025 Filed Dec 1, 2025 21:30 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 GiftCommon Stock 1,224 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-303941 · ownership.xml · nonDerivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,452

Read SEC document
July 31, 2025 Filed Aug 7, 2025 21:30 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 OtherCommon Stock 1,226 $8.43 $10,335.18
Disclosure

SEC source: 0000950170-25-105258 · ownership.xml · nonDerivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,676

F1 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,226 shares by the Reporting Person on 07/31/2025 pursuant to the Issuer's Employee Stock Purchase Plan.

Read SEC document
July 16, 2025 Filed Jul 18, 2025 20:30 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 SaleCommon Stock 1,296 $9.29 $12,033.36
Disclosure

SEC source: 0000950170-25-096948 · ownership.xml · nonDerivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,450

F1 · price: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.

Read SEC document
May 19, 2025 Filed May 19, 2025 20:04 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 PurchaseCommon Stock 3,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-074304 · ownership.xml · nonDerivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,746

F1 · price: The purchase prices ranged from $8.8465 to $9.2825.

Read SEC document
February 10, 2025 Filed Feb 12, 2025 22:16 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 SaleCommon Stock 3,777 $15.50 $58,558.61
Disclosure

SEC source: 0000950170-25-019005 · ownership.xml · nonDerivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,746

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.

Read SEC document
February 05, 2025 Filed Feb 7, 2025 21:44 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 GrantStock Options (Right to buy) · Derivative 110,500 $14.65 Strike: $14.65 $1,618,825.00
Disclosure

SEC source: 0000950170-25-016389 · ownership.xml · derivative · entry 3

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,500

Underlying: Common Stock · 110,500 shares

Expires 2035-02-05

F3 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period.

Read SEC document
February 05, 2025 Filed Feb 7, 2025 21:44 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 GrantCommon Stock 23,400 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-016389 · ownership.xml · nonDerivative · entry 2

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,523

F2 · shares: Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company.

Read SEC document
February 05, 2025 Filed Feb 7, 2025 21:44 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 GrantCommon Stock 18,500 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-016389 · ownership.xml · nonDerivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,123

F1 · shares: Award of restricted stock units ("RSUs"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested.

Read SEC document
June 14, 2024 Filed Jun 17, 2024 13:26 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 PurchaseCommon Stock 1,250 $20.03 $25,037.25
Disclosure

SEC source: 0001562180-24-005118 · primarydocument.xml · nonDerivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,623

Read SEC document
February 07, 2024 Filed Feb 9, 2024 21:05 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 GrantStock Options (Right to buy) · Derivative 70,000 $22.28 Strike: $22.28 $1,559,600.00
Disclosure

SEC source: 0001562180-24-001222 · primarydocument.xml · derivative · entry 5

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2034-02-07

F5 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period.

Read SEC document
February 07, 2024 Filed Feb 9, 2024 21:05 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 GrantCommon Stock 11,700 $0.00 $0.00
Disclosure

SEC source: 0001562180-24-001222 · primarydocument.xml · nonDerivative · entry 4

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,373

F4 · shares: Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company.

Read SEC document
February 07, 2024 Filed Feb 9, 2024 21:05 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 GrantCommon Stock 35,000 $0.00 $0.00
Disclosure

SEC source: 0001562180-24-001222 · primarydocument.xml · nonDerivative · entry 3

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,673

F3 · shares: Award of restricted stock units ("RSUs"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested.

Read SEC document
January 31, 2024 Filed Feb 9, 2024 21:05 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 OtherCommon Stock 1,183 $17.42 $20,607.86
Disclosure

SEC source: 0001562180-24-001222 · primarydocument.xml · nonDerivative · entry 2

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,673

F2 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,183 shares by the Reporting Person on 01/31/2024 pursuant to the Issuer's Employee Stock Purchase Plan.

Read SEC document
July 31, 2023 Filed Feb 9, 2024 21:05 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 OtherCommon Stock 862 $18.12 $15,619.44
Disclosure

SEC source: 0001562180-24-001222 · primarydocument.xml · nonDerivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,490

F1 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 862 shares by the Reporting Person on 07/31/2023 pursuant to the Issuer's Employee Stock Purchase Plan.

Read SEC document
June 13, 2023 Filed Jun 14, 2023 20:20 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 SaleCommon Stock 577 $22.31 $12,872.87
Disclosure

SEC source: 0001562180-23-005152 · primarydocument.xml · nonDerivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,628

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.

Read SEC document
February 02, 2023 Filed Feb 3, 2023 22:00 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 GrantStock Options (Right to buy) · Derivative 110,000 $28.55 Strike: $28.55 $3,140,500.00
Disclosure

SEC source: 0001562180-23-000953 · primarydocument.xml · derivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 110,000 shares

Expires 2033-02-02

F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period.

Read SEC document
June 13, 2022 Filed Jun 15, 2022 20:12 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 GrantStock Options (Right to buy) · Derivative 230,000 $15.60 Strike: $15.60 $3,588,000.00
Disclosure

SEC source: 0001562180-22-005117 · primarydocument.xml · derivative · entry 2

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 230,000

Underlying: Common Stock · 230,000 shares

Expires 2032-06-13

F2 · derivative.exercise_date: Twenty five percent (25%) of the total number of shares underlying the option shall vest on June 13, 2023, and one-thirty-sixth (1/36th) of the remaining shares underlying the option shall vest monthly thereafter on the last day of each month, subject to the reporting person's continuous service on the relevant vesting dates.

Read SEC document
June 13, 2022 Filed Jun 15, 2022 20:12 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 GrantCommon Stock 3,205 $0.00 $0.00
Disclosure

SEC source: 0001562180-22-005117 · primarydocument.xml · nonDerivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,205

F1 · shares: Award of Restricted Stock Units that vest 50% of the shares on June 13, 2023 and the remaining 50% of the shares on June 13, 2024.

Read SEC document
March 16, 2022 Filed Mar 17, 2022 17:23 UTC OptiNose, Inc. OPTN · Entity 79464 SaleCommon Stock 4,617 $2.11 $9,741.87
Disclosure

SEC source: 0001494650-22-000029 · wf-form4_164753781398908.xml · nonDerivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,726

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Read SEC document
January 11, 2022 Filed Jan 12, 2022 21:02 UTC OptiNose, Inc. OPTN · Entity 79464 GrantStock Option (Right to Buy) · Derivative 66,185 $0.00 Strike: $1.85 $0.00
Disclosure

SEC source: 0001494650-22-000006 · wf-form4_164202134380026.xml · derivative · entry 3

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,185

Underlying: Common Stock · 66,185 shares

Expires 2026-01-11

F3 · shares: Represents the maximum number of options eligible to vest during the 4-year vesting period subject to the achievement of certain performance-based objectives relating to the trading price of OptiNose, Inc. common stock. If the minimum performance criteria relating to the trading price of OptiNose, Inc. common stock is not achieved, then none of the options will be eligible to vest.

F4 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period, commencing on January 11, 2022, subject to the achievement of certain performance-based objectives relating to the trading price of OptiNose, Inc. common stock and continued service with the Issuer.

Read SEC document
January 11, 2022 Filed Jan 12, 2022 21:02 UTC OptiNose, Inc. OPTN · Entity 79464 GrantStock Option (Right to Buy) · Derivative 85,095 $0.00 Strike: $1.85 $0.00
Disclosure

SEC source: 0001494650-22-000006 · wf-form4_164202134380026.xml · derivative · entry 2

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,095

Underlying: Common Stock · 85,095 shares

Expires 2032-01-11

F2 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on January 11, 2022. Twenty-five percent (25%) of the option vests and becomes exercisable on January 11, 2023, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer.

Read SEC document
January 11, 2022 Filed Jan 12, 2022 21:02 UTC OptiNose, Inc. OPTN · Entity 79464 GrantCommon Stock 56,730 $0.00 $0.00
Disclosure

SEC source: 0001494650-22-000006 · wf-form4_164202134380026.xml · nonDerivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,343

F1 · shares: Represents the grant of restricted stock units (RSUs). Twenty-five percent (25%) of the RSUs vest on January 11, 2023, and the balance vests in equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Each RSU represents the right to receive one share of common stock of OptiNose, Inc.

Read SEC document
December 16, 2021 Filed Dec 17, 2021 14:27 UTC OptiNose, Inc. OPTN · Entity 79464 SaleCommon Stock 580 $1.64 $951.20
Disclosure

SEC source: 0001494650-21-000155 · wf-form4_163975122697686.xml · nonDerivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,613

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Read SEC document
September 16, 2021 Filed Sep 17, 2021 17:53 UTC OptiNose, Inc. OPTN · Entity 79464 SaleCommon Stock 578 $2.79 $1,612.04
Disclosure

SEC source: 0001494650-21-000108 · wf-form4_163190116827344.xml · nonDerivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,193

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Read SEC document
June 17, 2021 Filed Jun 17, 2021 22:35 UTC OptiNose, Inc. OPTN · Entity 79464 SaleCommon Stock 576 $3.73 $2,148.48
Disclosure

SEC source: 0001494650-21-000076 · wf-form4_162396931494948.xml · nonDerivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,771

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Read SEC document
March 15, 2021 Filed Mar 17, 2021 22:11 UTC OptiNose, Inc. OPTN · Entity 79464 SaleCommon Stock 2,304 $3.92 $9,031.68
Disclosure

SEC source: 0001494650-21-000041 · wf-form4_161601907384985.xml · nonDerivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,347

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Read SEC document
March 04, 2021 Filed Mar 8, 2021 22:19 UTC OptiNose, Inc. OPTN · Entity 79464 GrantStock Option (Right to Buy) · Derivative 80,000 $3.51 Strike: $3.51 $280,800.00
Disclosure

SEC source: 0001494650-21-000018 · wf-form4_161524193371157.xml · derivative · entry 2

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2031-03-04

F2 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on March 4, 2021. Twenty-five percent (25%) of the option vests and becomes exercisable on March 4, 2022, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer.

Read SEC document
March 04, 2021 Filed Mar 8, 2021 22:19 UTC OptiNose, Inc. OPTN · Entity 79464 GrantCommon Stock 53,333 $0.00 $0.00
Disclosure

SEC source: 0001494650-21-000018 · wf-form4_161524193371157.xml · nonDerivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,084

F1 · shares: Represents the grant of restricted stock units (RSUs). Twenty-five percent (25%) of the RSUs vest on March 15, 2022, and the balance vests in equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Each RSU represents the right to receive one share of common stock of OptiNose, Inc.

Read SEC document
September 23, 2020 Filed Sep 23, 2020 20:47 UTC OptiNose, Inc. OPTN · Entity 79464 PurchaseCommon Stock 2,500 $3.90 $9,742.50
Disclosure

SEC source: 0001494650-20-000125 · wf-form4_160089405254597.xml · nonDerivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,751

F1 · balance_after: Includes 490 shares acquired under the Company's employee stock purchase plan on June 30, 2020 at a per share purchase price of $7.34.

Read SEC document
March 06, 2020 Filed Mar 9, 2020 11:06 UTC OptiNose, Inc. OPTN · Entity 79464 GrantRestricted Stock Units · Derivative 30,567 $0.00 Strike: $5.41 $0.00
Disclosure

SEC source: 0001494650-20-000031 · wf-form4_158375195126807.xml · derivative · entry 2

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,567

Underlying: Common Stock · 30,567 shares

Expires not disclosed

F2 · derivative.exercise_date: Each restricted stock unit (RSU) represents the right to receive one share of common stock of OptiNose, Inc. Twenty-five percent (25%) of the RSUs vest on March 6, 2021, and the balance vests in equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.

F2 · derivative.expiration_date: Each restricted stock unit (RSU) represents the right to receive one share of common stock of OptiNose, Inc. Twenty-five percent (25%) of the RSUs vest on March 6, 2021, and the balance vests in equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.

Read SEC document
March 06, 2020 Filed Mar 9, 2020 11:06 UTC OptiNose, Inc. OPTN · Entity 79464 GrantStock Option (Right to Buy) · Derivative 45,850 $5.41 Strike: $5.41 $248,048.50
Disclosure

SEC source: 0001494650-20-000031 · wf-form4_158375195126807.xml · derivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,850

Underlying: Common Stock · 45,850 shares

Expires 2030-03-06

F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on March 6, 2020. Twenty-five percent (25%) of the option vests and becomes exercisable on March 6, 2021, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer.

Read SEC document
March 06, 2020 Filed Mar 17, 2021 22:04 UTC Amendment OptiNose, Inc. OPTN · Entity 79464 GrantStock Option (Right to Buy) · Derivative 45,850 $5.41 Strike: $5.41 $248,048.50
Disclosure

SEC source: 0001494650-21-000032 · wf-form4a_161601863167747.xml · derivative · entry 2

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,850

Underlying: Common Stock · 45,850 shares

Expires 2030-03-06

F2 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on March 6, 2020. Twenty-five percent (25%) of the option vests and becomes exercisable on March 6, 2021, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer.

Read SEC document
March 06, 2020 Filed Mar 17, 2021 22:04 UTC Amendment OptiNose, Inc. OPTN · Entity 79464 GrantCommon Stock 30,567 $0.00 $0.00
Disclosure

SEC source: 0001494650-21-000032 · wf-form4a_161601863167747.xml · nonDerivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,328

F1 · shares: Represents the grant of restricted stock units (RSUs). Twenty-five percent (25%) of the RSUs vest on March 15, 2021, and the balance vests in equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Each RSU represents the right to receive one share of common stock of OptiNose, Inc.

Read SEC document
December 31, 2019 Filed Jan 16, 2020 21:11 UTC OptiNose, Inc. OPTN · Entity 79464 GrantCommon Stock 2,695 $6.13 $16,520.35
Disclosure

SEC source: 0001494650-20-000002 · wf-form5_157920905942139.xml · nonDerivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,761

F1 · kind: Shares acquired under the Optinose, Inc. 2017 Employee Stock Purchase Plan on December 31, 2019 in a transaction exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Read SEC document
June 28, 2019 Filed Jul 9, 2019 11:30 UTC OptiNose, Inc. OPTN · Entity 79464 GrantCommon Stock 941 $5.64 $5,307.24
Disclosure

SEC source: 0001494650-19-000067 · wf-form4_156267179853617.xml · nonDerivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,066

F1 · kind: Shares acquired under the OptiNose, Inc. 2017 Employee Stock Purchase Plan on June 28, 2019 in a transaction exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Read SEC document
February 28, 2019 Filed Mar 6, 2019 23:27 UTC OptiNose, Inc. OPTN · Entity 79464 GrantStock Option (Right to Buy) · Derivative 82,500 $0.00 Strike: $7.42 $0.00
Disclosure

SEC source: 0001494650-19-000027 · wf-form4_155191483222043.xml · derivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,500

Underlying: Common Stock · 82,500 shares

Expires 2029-02-28

F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on February 28, 2019. Twenty-five percent (25%) of the option vests and becomes exercisable on February 28, 2020, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer.

Read SEC document
June 29, 2018 Filed Jan 8, 2019 21:54 UTC OptiNose, Inc. OPTN · Entity 79464 GrantCommon Stock 3,125 $13.60 $42,500.00
Disclosure

SEC source: 0001494650-19-000010 · wf-form5_154698442574019.xml · nonDerivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,125

F1 · kind: Shares acquired under the Optinose, Inc. 2017 Employee Stock Purchase Plan on June 29, 2018 in a transaction exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Read SEC document
October 12, 2017 Filed Oct 16, 2017 16:41 UTC OptiNose, Inc. OPTN · Entity 79464 GrantStock Option (Right to Buy) · Derivative 72,197 $0.00 Strike: $16.00 $0.00
Disclosure

SEC source: 0001104659-17-062326 · a4.xml · derivative · entry 1

Goldan Keith A. · CIK 0001495411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,197

Underlying: Common Stock · 72,197 shares

Expires 2027-10-11

F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on October 12, 2017. Twenty-five percent (25%) of the option vests and becomes exercisable on October 12, 2018, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.